Key facts
- Notable investors include Mission BioCapital, Age 1, Conscience, Ferocity Capital, LongGame — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Aperture Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aperture Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aperture Therapeutics
Developer of oligonucleotide therapeutics designed to treat neurodegenerative diseases and brain aging. The company offers drug candidates based on human genetic resilience, enabling the developer of treatments that mimic naturally occurring protective genetic effects to combat age- and injury-related neurodegeneration.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2022
- Employees
- 8
- Website
- aperturetx.com/
- Ownership
- Privately Held (backing)
Aperture Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aperture Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aperture Therapeutics in its N-PORT filings yet. We sweep new filings monthly.